chronic renal failure; diastolic function; left ventricular hypertrophy Background. Left ventricular hypertrophy is frequently noted in patients with moderate to severe chronic renal failure not requiring dialysis. Recently, several studies have shown reversal of myocardial hypertrophy in endstage renal disease with long-term pharmacological Introduction control of blood pressure, but it is unclear whether left ventricular mass regresses or normalizes with antihy-Cardiovascular disease is the leading cause of death in pertensive treatment of patients with earlier stages of end-stage renal failure, representing 43-52% of overall chronic renal failure.
control of blood pressure, but it is unclear whether left ventricular mass regresses or normalizes with antihy-Cardiovascular disease is the leading cause of death in pertensive treatment of patients with earlier stages of end-stage renal failure, representing 43-52% of overall chronic renal failure.
mortality [1] [2] [3] . Indeed, cardiovascular mortality in Methods. Seventy-two undialysed patients with chronic patients on renal replacement therapy is 10-20 times renal failure, chronic mild-to-moderate hypertension, more common than in the general population [4] [5] [6] [7] . and left ventricular hypertrophy were randomly Left ventricular hypertrophy is an independent factor assigned in a prospective study to either the captopril related to overall mortality in uraemic patients [8] [9] [10] [11] . (n=36) or enalapril group (n=36). Blood pressure In non-uraemic hypertensive patients with left measurements, echocardiographic and Doppler para-ventricular hypertrophy, prolonged restoration of meters were evaluated before treatment and at 6 and normal loading conditions with most classes of antihy-12 months of therapy.
pertensive drugs, excluding direct vasodilators and Results. During follow-up, six patients developed side-diuretics, leads to significant decrease in left ventricular eÂects including dry cough, taste disturbances, skin muscle mass index and left ventricular wall thickness rash and gastric intolerance. In the captopril group and to improvement of left ventricular systolic and there was a decrease in mean left ventricular mass diastolic function [12, 13] . Regression of left ventricular index by 12% after 6 months of treatment, which hypertrophy in end-stage renal disease has been demondecreased by 20% after 12 months treatment. For strated after treatment with recombinant human enalapril, the average reduction of myocardial mass erythropoietin [14, 15] and after renal transplantation after 6 months treatment was 14% and after 12 months [5, 16] . Although recently, several experimental and treatment, the decrease was 19%. In both treatment clinical studies have shown reversal of myocardial groups there was significant improvement of left ventri-hypertrophy in end-stage renal disease with long-term cular filling dynamics. No deterioration of left ventricu-vigorous pharmacological control of blood pressure lar systolic function was observed.
[17-20 ], it is unclear whether left ventricular mass and Conclusions. Our results confirm that antihypertensive left ventricular filling dynamics are improved by antihymonotherapy with the ACE inhibitors, captopril and pertensive treatment of patients with earlier stages of enalapril, in patients with chronic renal failure results chronic renal failure. Moreover, the impact of regresin regression of left ventricular mass index associated sion of left ventricular hypertrophy on systolic function with a significant improvement in the diastolic function in this population remains controversial. Previous studof the left ventricle without a demonstrable deteriora-ies have reported no consistent improvement in left tion in left ventricular systolic performance. ventricular systolic function in treated patients with essential hypertension and end-stage renal failure, desKey words: ACE inhibition; blood pressure control; pite a significant reduction in left ventricular mass [12, 13, 18] . We investigated whether long-term antihypertensive treatment with captopril and enalapril decreases left serial measurements of blood pressure, heart rate (electrocar- 
Subjects and methods

Echocardiographic and Doppler measurements
Echocardiographic studies were obtained before treatment
Patient population
and at 6th and 12th months after the individual doses of studied drugs were reached. Seventy-two patients ( 34 men and 38 women, mean age 43.7 M-mode echocardiographic examination was performed years, range 24-61 years) with moderate to severe chronic with two-dimensional monitoring using ATL Ultramark-9 renal failure not requiring dialysis (mean serum creatinine duplex echocardiograph (Advanced Technologies Labor-0.49 mmol/l, range 0.32 to 0.54 mmol/l ) were enrolled in the atories, Bellevue, WA, USA) with a 2. meters were estimated with pulsed Doppler examinations to None of the patients had echocardiographic regional wall obtain peak velocity of early (E ) and late diastolic filling motion abnormalities or a left ventricular shortening fraction (A), and the ratio ( E/A) of early to late diastolic flow less than 25%. Other secondary causes of hypertension were velocity was calculated. ruled out by clinical examination and routine biological tests. Enrolled patients gave written informed consent for study participation; both the study protocol and the consent form Statistical analysis were approved by the Institutional Review Board.
Results are expressed as means±SD. Comparisons of parameters of cardiac structure and function at baseline with
Study design
those during treatment were performed by one-way analysis of variance with repeated measurements. Comparisons of The 72 recruited patients were randomly assigned to one of studied parameters between A and B groups were performed two treatment groups: group A (n=36) were given captopril by using Student's t test for unpaired observations. Simple and group B (n=36) enalapril. The study design consisted linear regression analysis was performed to correlate changes of three phases: a single-blind placebo phase, a 6-to 8-week in left ventricular mass with changes in left ventricular phase of drug titration and a 12-month maintenance phase.
shortening fraction or in diastolic filling parameters during A complete medical history was obtained and a physical treatment. A P value less than 0.05 was considered significexamination, complete blood count, urinalysis, routine serum ant [23] . chemistry analysis, electrocardiogram, echocardiographic and Doppler examinations and thoracic radiographs were performed. All blood pressure readings were made by the Results same investigator, who used the same calibrated mercury sphygmomanometer throughout the study.
During the placebo phase, eligible patients received one Characteristics of the study population on entry placebo tablet per day for 1-2 weeks. Patients with a sitting There was no significant diÂerence between the two diastolic blood pressure of 95-116 mmHg after the placebo phase were eligible for further participation in the study.
groups at baseline ( Table 1 ). There was a slight diÂer-During the titration phase, the initial doses of captopril ence between the two groups with respect to left and enalapril were 6.25 and 2.5 mg/day respectively [21 ]. ventricular mass index, which did not reach statistical The dosage was increased every 2weeks by 6.25 or 2.5 mg significance. increments, respectively, until 'goal' BP, defined as a sitting diastolic BP of <90 mmHg or a reduction in diastolic BP of
Treatment tolerance
Á10 mmHg compared to the pretreatment and baseline measurements, was achieved. Patients who did not achieve All patients with chronic renal failure completed the the 'goal' BP during titration phase were dropped from placebo phase and 72 patients were included in the the study. study; 'goal' blood pressure during titration phase was Patients who achieved the 'goal' blood pressure at the end not achieved in 14 patients. Six of 58 (10.3%) patients of the titration phase were then evaluated at the 6th and included in the maintenance phase of study developed 12th months of treatment. Evaluation during the maintenance phase was similar to baseline evaluation and included side-eÂects during the follow-up period. Four patients There was no significant diÂerence between the two adverse eÂects and were withdrawn prematurely after groups in terms of left ventricular dimensions, wall a mean of 26±19 days. The reasons in both groups thickness and left ventricular mass index after 6 and included dry cough (n=2), taste disturbances (n=1), 12 months treatment. The decrement in left ventricular skin rash (n=2), and gastric intolerance (n=1). Two hypertrophy was not correlated with the reduction in patients were withdrawn because they were inco-the systolic and diastolic blood pressure (for group A operative and it was impossible to regularly evaluated values were r=0.29 and 0.32; for group B values were of these patients. None of the patients developed fur-r=0.24 and 0.30 respectively, all P>0.05). ther significant impairment of renal function and significant hyperkalaemia during the follow-up period. EÂect of treatment on left ventricular diastolic function The mean age of the 50 patients completing the study was 44±10 years (range, 24-60 years) and there were Left ventricular peak early inflow velocity and ratio of 23 men and 27 women.
early to late inflow velocities increased at 6 months Twenty-eight patients received 23±8 mg of captopril compared with baseline values in patients in both (range 6.25-31.25 mg, median dose 25 mg) and 22 groups (Tables 2, 3 ). Conversely, peak late inflow patients received 10±2 mg of enalapril (range velocity decreased during treatment in both treatment 5-12.5 mg, median dose 10 mg) during 12 months.
groups. These overall changes after 6 months of treatment were significant for peak early and peak late inflow velocity and ratio of early to late inflow velocitEÂect of treatment on haemodynamic parameters and ies (all P<0.05). In both groups at 12 months, there laboratory data was further improvement in left ventricle dynamics, Both captopril and enalapril induced a significant evidenced by enhanced early filling with diminished decrease (P<0.05) in the systolic and diastolic blood late filling velocities. pressure values after the end of the titration phase, There were only slight diÂerences in left ventricular which remained unchanged during maintenance filling dynamics between patients receiving captopril therapy ( Tables 2, 3 ). For captopril, the average reduc-and enalapril after both 6 and 12 months of treatment, tions were 12.7 and 14.2% in systolic and diastolic which did not reach significant values. The improveblood pressure respectively. In the enalapril group, ment in the ratio of early to late inflow velocities systolic and diastolic blood pressure was reduced by during treatment in both groups was not correlated 11.9 and 12.3% respectively. There was no significant with the regression of left ventricular mass index (for diÂerence between the two groups.
group A r=0.33; for group B r=0.36 respectively, all In patients receiving captopril or enalapril there were P>0.05). no significant changes in heart rate from the baseline levels (78±7 and 76±13 beats/min respectively) to EÂect of treatment on left ventricular systolic function those after 6 and 12 months of treatment (77±9, and 78±8 beats/min in group A and 76±9, and 75±9 Left ventricular shortening fraction was unchanged in the captopril group as well as in enalapril group after beats/min in group B respectively). There were no significant changes in creatinine and haemoglobin 6 months, but significantly increased after 12 months of therapy over baseline levels ( Tables 2, 3 ). These levels from the initial values in both groups during treatment ( Tables 2, 3 ) .
overall changes in left ventricular shortening fraction during treatment were statistically significant in both ACE inhibitors have been shown to be the most drugs (P<0.05). There was a slight and insignificant eÂective in terms of regression of left ventricular muscle diÂerence in values of left ventricular shortening frac-mass in essential hypertension [24 ] . Previous studies tion between the groups of patients. There was no in experimental animals and human subjects on cardiolinear relationship between regression of left ventricular protective and cardioreparative properties of these hypertrophy and overall changes in shortening fraction agents suggest that they would be useful in preventing (for group A r=0.36; for group B r=0.34 respectively, and reversing the myocardial structural changes in left all P>0.05). ventricular hypertrophy [25] [26] [27] . Left ventricular hypertrophy is frequently noted in patients with moderate to severe chronic renal failure Discussion not requiring dialysis. Greaves et al. [28 ] have observed that of 38 undialysed patients with chronic renal Regression of left ventricular hypertrophy failure, 63% had abnormal echocardiogram, and left ventricular hypertrophy was the most common finding Antihypertensive treatment with captopril or enalapril was compared in patients with chronic renal failure. (24%). Since left ventricular hypertrophy is a cardio-vascular risk in both uraemic and non-uraemic popula-both. In the present study, the decrement in left ventricular hypertrophy was not correlated with the tions, the prevention of hypertrophy, its early detection, and reduction of left ventricular mass index reduction in the systolic and diastolic blood pressure.
In agreement with our findings, other clinical and at early stages of chronic renal failure appear to be promising for the reduction of cardiovascular events experimental studies have shown that the left ventricular mass correlated poorly with blood pressure level in patients with chronic uraemia [4, 27, 29, 30] .
In the last few years a growing number of experi-during both the development and the reversal of hypertensive left ventricular hypertrophy [13, 37] . However, mental and clinical reports have analysed the structural left ventricular changes during ACE-inhibition in several studies reported the crucial role of a decrease in blood pressure diminishing in the reduction of left uraemia. The results are controversial. Rambausek et al. [31 ] have described left ventricular hypertrophy ventricular mass in end-stage renal disease, as well as in essential hypertension [17, 29, 35] . The disparity in development and progression in uraemic animals despite blood pressure normalization by ACE inhibitors. the reported findings may be attributable to the diÂer-ent antihypertensive drugs used in these studies, and These results are in accordance with recent findings of Roithinger et al. [32 ] , who concluded that the ACE to interstudy diÂerences in methods of blood pressure measurements (casual blood pressure versus 24-h inhibitor lisinopril, at a dose which left the blood pressure unchanged throughout the study period, was ambulatory blood pressure monitoring). not able to induce reduction of left ventricular mass.
In contrast, the data in our study indicate that in Changes in diastolic function during treatment patients with chronic renal failure and moderate arterial hypertension, long-term treatment with the ACE The present study showed that regression of left ventricular hypertrophy during antihypertensive treatment inhibitors, captopril or enalapril, significantly lowered arterial pressure and reduced left ventricular hyper-of chronic renal failure patients with ACE inhibitors captopril and enalapril is associated with significant trophy. A significant diÂerence in respect of blood pressure diminishing and reduction of left ventricular improvement in the diastolic function of the left ventricle. In contrast with our findings, Roithinger et al. mass index between the two treatments was not evident. In agreement with our results, London et al. [11 ] [32] were unable to show improvement in diastolic filling in patients with chronic renal failure receiving showed that despite similar eÂects on blood pressure in patients with left ventricular hypertrophy and end-an ACE inhibitor.
It is speculated that reduction in left ventricular stage renal failure, a reduction in left ventricular mass and volume was observed with ACE inhibition but not mass with antihypertensive treatment increases the fibrosis/myocardial muscle fibre ratio, leaving the ventwith calcium-channel blockade.
In the present study, left ventricular mass index was ricle less compliant and perhaps with worsened diastolic function [12, 13] . The data in this study, as well found to be reduced by 12 and 14% after 6 months of treatment with captopril and enalapril respectively. as that of others, do not support this concept, since regression of hypertrophy was accompanied by The degree of left ventricular mass index reduction in our study was in agreement with some short-term improvement in left ventricular filling dynamics in all reports [35] . previous studies of ACE inhibitor treatment in patients with essential hypertension and end-stage renal failure [11, 24, 33] .
Changes in systolic function during treatment The time course of regression of left ventricular hypertrophy during antihypertensive therapy has been There has been some concern, based on a previous experimental study, that regression of left ventricular evaluated in several studies. In some clinical reports a reduction in posterior wall thickness and left ventricu-hypertrophy with antihypertensive treatment might lead to a deterioration of left ventricular systolic perlar mass index occurs as early as 4 weeks after the beginning of treatment, with further reduction during formance [38] . However, this concern has not been borne out by clinical studies that have shown either the subsequent 1-4 months and no significant change thereafter for up to 1 year [13, 34] . In contrast, several no change, or an improvement, in left ventricular systolic function after regression of left ventricular studies have clearly demonstrated that the magnitude of the reduction in left ventricular mass index is related hypertrophy in essential hypertension, even when treatment was withdrawn and blood pressure had increased to the duration of treatment [35, 36 ] . In our study, left ventricular mass index continued to decrease with again [35, 36 ] . We have also demonstrated no deterioration in left ventricular systolic function after reduction continuous treatment with ACE inhibitors, and after 12 months was 20 and 19% less than pretreatment of left ventricular mass with antihypertensive treatment of patients with end-stage renal disease [18 ] . In the values for captopril and enalapril groups respectively. The data herein indicate that the period of 3-6 months present study, left ventricular shortening fraction was unaltered in both groups after 6 months and significused in most previous studies is insuÃcient to document the time course of left ventricular mass reduction. antly increased after 12 months of treatment. Our findings of left ventricular shortening fraction It is unclear whether the regression of left ventricular hypertrophy is due to a lowering of blood pressure or dynamics after regression of left ventricular hypertrophy confirm those of previous reports [18, 35] . to a direct eÂect of the drugs on the myocardium, or decrease in cardiovascular morbidity and mortality Assisi, Italy, 1995; 373-376 rates are necessary. 20 . Suzuki H, Schaefer L, Schaefer RM et al. Long-term eÂects of converting enzyme inhibition on the heart in experimental uraemia: prevention of cardiac hypertrophy and amelioration of
